Metagenomi (NASDAQ:MGX) Posts Earnings Results, Misses Expectations By $0.02 EPS

Metagenomi (NASDAQ:MGX) released its quarterly earnings results on Thursday. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.02), FiscalAI reports. The company had revenue of $3.91 million for the quarter, compared to analyst estimates of $7.33 million. Metagenomi had a negative return on equity of 44.91% and a negative net margin of 348.54%.

Metagenomi Stock Down 8.1%

NASDAQ:MGX traded down $0.13 during trading hours on Friday, reaching $1.48. 472,549 shares of the stock were exchanged, compared to its average volume of 202,132. The firm has a 50 day simple moving average of $1.59 and a 200-day simple moving average of $1.93. Metagenomi has a 52 week low of $1.23 and a 52 week high of $3.95. The stock has a market capitalization of $55.57 million, a P/E ratio of -0.62 and a beta of 0.45.

Institutional Investors Weigh In On Metagenomi

Several institutional investors and hedge funds have recently made changes to their positions in MGX. XTX Topco Ltd lifted its stake in Metagenomi by 353.4% during the fourth quarter. XTX Topco Ltd now owns 68,994 shares of the company’s stock worth $112,000 after purchasing an additional 53,778 shares during the last quarter. Quadrature Capital Ltd bought a new stake in Metagenomi during the fourth quarter valued at $55,000. Bridgeway Capital Management LLC increased its stake in Metagenomi by 102.1% during the fourth quarter. Bridgeway Capital Management LLC now owns 395,800 shares of the company’s stock valued at $641,000 after purchasing an additional 200,000 shares during the last quarter. Panagora Asset Management Inc. acquired a new stake in shares of Metagenomi during the fourth quarter worth $53,000. Finally, Wells Fargo & Company MN raised its holdings in shares of Metagenomi by 16.1% during the fourth quarter. Wells Fargo & Company MN now owns 118,410 shares of the company’s stock worth $192,000 after purchasing an additional 16,402 shares during the period.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Metagenomi in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Metagenomi Company Profile

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.